12:00 AM
 | 
Jun 18, 2007
 |  BioCentury  |  Finance

Idenix: IIb or not IIb

Despite positive results for its valopicitabine in a triple combination Phase I/II trial for hepatitis C, Idenix Pharmaceuticals Inc. (IDIX) fell $0.53 to $6.70 on Tuesday. The problem was that the company disclosed it would conduct an additional Phase IIb trial that analysts hadn't factored into their models. As a result, two sellsiders downgraded the stock.

IDIX (Cambridge, Mass.) had hoped that valopicitabine (NM283) would work as part of a double combination with pegylated interferon. But when the company reported results from two other Phase IIb trials of the ribonucleoside analog plus pegylated IFN in April, the final data from one study showed no...

Read the full 502 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >